Innovative Inhaled Drug Delivery Developer Aerami Therapeutics to Merge with Special Purpose Acquisition Company FoxWayne Enterprises Acquisition Corp. to Become Public Company
07 déc. 2021 08h35 HE | Aerami Therapeutics Holdings, Inc.
New entity poised to accelerate the development of Aerami’s diverse pipeline ofnext-generation inhaled therapies AER-901, Aerami’s proprietary inhaled, nebulized formulation of imatinib, targeted to...